Reconstruction of peri-implant osseous defects: a multicenter randomized trial by Jepsen, K et al.
For Peer Review
 
 
 
 
 
 
Reconstruction of peri-implant osseous defects:  
A multicentre Randomized Trial 
 
 
Journal: Journal of Dental Research 
Manuscript ID JDR-15-0407.R4 
Manuscript Type: Research Reports 
Date Submitted by the Author: n/a 
Complete List of Authors: Jepsen, Karin; University of Bonn, Periodontology 
Jepsen, Soren; University of Bonn, Periodontology 
Laine, Marja; ACTA, Periodontology 
Anssari Moin, David; ACTA, Periodontology 
Pilloni, Andrea; University of Rome, Periodontics 
Zeza, Blerina; University of Rome, Periodontics 
Sanz, Mariano; Facultad de Odontologia., Periodontology 
Ortiz-Vigon, Alberto; Univ. Complutense de Madrid, Facultad de 
Odontologia, Periodontology 
Roos-Jansaker, Ann-Marie; Kristianstad University, Department of Health 
Sciences 
Renvert, Stefan; Kristianstad University, Department of Health Sciences 
Keywords: 
Bone loss, Peri-implant infection(s), Bone remodeling/regeneration, 
Surface chemistry/properties, Surgery, Biomaterial(s) 
Abstract: 
There is a paucity of data for the effectiveness of reconstructive procedures 
in the treatment of peri-implantitis. The objective of this study was to 
compare reconstruction of peri-implant osseous defects with porous 
titanium granules (OFD+PTG) with open flap debridement (OFD).  
Sixtythree patients (36 female, 27 male; age: 58.4 ± 12.3 years), 
contributing one circumferential peri-implant intra-osseous defect were 
included in a multi-national, multicentre randomized trial using a parallel 
group design. Following open flap debridement and surface 
decontamination using titanium brushes and hydrogen peroxide, 33 defects 
received porous titanium granules. The implants were not submerged. All 
patients received adjunctive perioperative systemic antibiotics. The primary 
outcome variable defect fill was assessed on digitalized radiographs. 
Clinical measurements of probing depth (PPD), bleeding on probing (BoP), 
suppuration (PuS) and plaque were taken by blinded examiners.  
After 12 months the test group (OFD+PTG) showed a mean radiographic 
defect fill (mesial/distal) of 3.6/3.6 mm compared to 1.1/1.0 in the control 
group (OFD). Differences were statistically significant in favour of the test 
group (p < 0.0001). The OFD+PTG group showed a mean reduction in PPD 
of 2.8 mm compared to 2.6 mm in the OFD group. BoP was reduced from 
89.4% to 33.3% for the test and from 85.8% to 40.4% in the control 
group. There was no significant difference in complete resolution of peri-
implantitis (PPD≤4 mm and no BOP at 6 implant sites and no further bone 
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loss) as this finding was accomplished at 30% of implants in the test and 
23% of implants in the control group.  
Reconstructive surgery using PTG resulted in significantly enhanced 
radiographic defect fill compared with OFD. Limitations in the lack of ability 
to discern biomaterial and osseous tissue could not be verified to 
determine new bone formation. Similar improvements according to clinical 
measures were obtained following both surgical treatment modalities.  
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Abstract   
 
There is a paucity of data for the effectiveness of reconstructive procedures in the 
treatment of peri-implantitis. The objective of this study was to compare 
reconstruction of peri-implant osseous defects with porous titanium granules 
(OFD+PTG) with open flap debridement alone (OFD).  
Sixtythree patients (36 female, 27 male; age: 58.4 ± 12.3 years), contributing one 
circumferential peri-implant intra-osseous defect were included in a multi-national, 
multicentre randomized trial using a parallel group design. Following open flap 
debridement and surface decontamination using titanium brushes and hydrogen 
peroxide, 33 defects received porous titanium granules. The implants were not 
submerged. All patients received adjunctive perioperative systemic antibiotics. The 
primary outcome variable defect fill was assessed on digitalized radiographs. Clinical 
measurements of probing depth (PPD), bleeding on probing (BoP), suppuration 
(PuS) and plaque were taken by blinded examiners.  
After 12 months the test group (OFD+PTG) showed a mean radiographic defect fill 
(mesial/distal) of 3.6/3.6 mm compared to 1.1/1.0 in the control group (OFD). 
Differences were statistically significant in favour of the test group (p < 0.0001). The 
OFD+PTG group showed a mean reduction in PPD of 2.8 mm compared to 2.6 mm 
in the OFD group. BoP was reduced from 89.4% to 33.3% for the test and from 
85.8% to 40.4% in the control group. There was no significant difference in complete 
resolution of peri-implantitis (PPD≤4 mm and no BOP at 6 implant sites and no 
further bone loss) as this finding was accomplished at 30% of implants in the test and 
23% of implants in the control group.  
Reconstructive surgery using PTG resulted in significantly enhanced radiographic 
defect fill compared with OFD. Limitations in the lack of ability to discern biomaterial 
and osseous tissue could not be verified to determine new bone formation. Similar 
improvements according to clinical measures were obtained following both surgical 
treatment modalities. 
Trial registration NCT02406001 
Key words: Debridement, peri-implantitis, surgical therapy, titanium granules, bone 
regeneration, dental/oral implants 
Page 3 of 30
http://mc.manuscriptcentral.com/jdr
Journal of Dental Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 3 
 
Introduction 
Peri-implant osseous defects are often the result of peri-implantitis defined as 
inflammation of peri-implant tissues accompanied by peri-implant bone loss with 
bleeding on probing and/or suppuration, with or without concomitant deepening of 
peri-implant pockets (Lang and Berglundh 2011). According to recent reviews, this 
infectious condition has a prevalence of 20% of patients (Mombelli et al. 2012; Klinge 
and Meyle 2012; Atieh et al. 2013; Derks and Tomasi 2015). 
Various protocols including mechanical debridement, the use of antiseptics and local 
or systemic antibiotics, as well as access and regenerative surgery have been 
proposed for the treatment of peri-implantitis. At present there is no reliable evidence 
to identify the most effective intervention for treating peri-implantitis (Esposito et al. 
2012). 
Surgical methods are commonly applied for the management of moderate and 
advanced peri-implantitis (Aljateeli et al. 2012). One of the goals of surgical therapy 
is access for implant surface decontamination. An anti-infective protocol, 
incorporating surgical access, surface decontamination and systemic antimicrobials 
was shown to be effective in a 12-months follow-up (Heitz-Mayfield et al. 2011). 
Regenerative procedures, using bone grafts or bone substitutes, sometimes in 
combination with membranes, aimed at reconstructing peri-implant osseous defects 
have shown variable results (Khoury and Buchmann 2001; Roos-Jansaker et al. 
2007a/b, 2011, 2014; Schwarz et al. 2009; 2010, Aghazedeh et al. 2012; Wiltfang et 
al. 2012). However, there is only limited evidence in the literature available to 
compare the clinical effectiveness of reconstructive and nonreconstructive 
procedures (Khoshkam et al. 2013).  
Recently porous titanium granules (PTG) have been introduced as an 
osteoconductive bone graft substitute for the treatment of peri-implant defects. A 
case report with human histology demonstrated that grafting of a peri-implant defect 
with PTG could support re-osseointegration of the implant with newly formed bone 
(Wohlfahrt et al. 2011). In a randomized controlled trial Wohlfahrt et al. (2012) 
compared open flap debridement (control) with a surgical procedure placing PTG 
(test) for augmentation of peri-implant osseous defects in a submerged surgical 
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 4 
technique and found significantly better radiographic peri-implant defect fill compared 
with the controls. In a case report the reconstruction of a peri-implant defect with 
PTG was preceded by implant surface debridement with a novel titanium brush and 
H2O2 (3%). Re-entry surgery after 6 months revealed a complete integration of the 
bone replacement material in new bone, with no signs of loose particles (Wohlfahrt & 
Lyngstadaas 2012). 
The objective of the present randomized trial was to compare reconstructive surgery 
of advanced peri-implant osseous defects with PTG to open flap debridement in a 
non-submerged technique, with the hypothesis of a significantly higher defect fill after 
12 months for the reconstructive procedure. 
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 5 
Material and Methods 
 
Study design 
The study was designed as a prospective multicentre, multi-national, randomized, 
parallel-group clinical trial of 12 months duration and registered at ClinicalTrials.gov 
(NCT02406001).  
All investigators attended calibration meetings where preliminary cases were 
discussed and used to standardize case selection, clinical measurement techniques 
and surgical procedures.  
On-site rules for the compilation of the data collection sheets for appropriate 
oversight were frequently reassured by a study monitor to ensure the validity of the 
data. 
Study population 
Study subjects were recruited consecutively from patients treated by experienced 
periodontists/implant dentists in Germany (University of Bonn), the Netherlands 
(Amsterdam, ACTA), Italy (Rome University), Spain (University Complutense Madrid) 
and Sweden (Kristianstad University). After thorough explanation of the study 
procedure and its associated risks and benefits each participant signed an informed 
consent in accordance with the Helsinki Declaration of 1975 as revised in 2008. The 
Ethical Committee for human subject trials in each institution approved the study 
protocol individually.  
Seventy informed and consenting patients above the age of 18 years of age with a 
diagnosis of peri-implantitis were enrolled in the study and surgery was performed. 
Seven patients were withdrawn early at surgery, as the defect around the implants 
did not meet the inclusion criteria. After surgery 63 patients (36 female and 27 male; 
mean age: 58.4 ± 12.3 (SD) years; range: 26 to 88 years) remained in the study 
(Test group n = 33, Control group n = 30). A study flow chart is presented as Figure 
1.  
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 6 
Inclusion criteria 
All implants had to be in function for more than 12 months. In patients with more than 
one peri-implant defect meeting the inclusion criteria only one implant per patient was 
defined as target (the most severe defect) and included in the study.  
Primary inclusion criteria  
By initial radiographic evaluation: 
• Intraosseous defect ≥ 3 mm on standard intraoral radiograph.  
By clinical evaluation: 
• Peri-implant probing depth (PD) ≥ 5 mm 
• Bleeding (BOP) and/or suppuration (PUS) 
Secondary inclusion criteria  
By intra-operative exploration: 
• Intra-osseous defect component ≥ 3 mm at the deepest point 
• 3 to 4 walls 
• Defect with at least 270 degrees (circumferential) 
• Defect angle ≤ 35 degrees (from axis of implant) 
Exclusion criteria 
• Subjects with diabetes mellitus (HbA1c ≥6.5). 
• Subjects taking corticosteroids or other anti-inflammatory prescription drugs. 
• Subjects taking medications known to induce gingival hyperplasia. 
• Subjects with a history of taking systemic antibiotics in the preceding month. 
• Patients pregnant or nursing. 
• Implants placed in grafted bone or previously augmented with bone /bone 
substitute. 
• Implants previously surgically treated for peri-implantitis. 
• Implant mobile. 
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 7 
Pre-surgical treatment and evaluation 
All necessary periodontal treatments were finished as evaluated by a full periodontal 
examination with recording of pocket probing depth (PPD), full-mouth bleeding and 
plaque scores at least 1 month prior to the peri-implant surgical procedure and to 
entry into the study. Pre-surgical interventions included oral hygiene instructions to 
the individual needs of the patient, non-surgical periodontal/periimplant and surgical 
periodontal therapy. 
Patients who met all criteria for inclusion, verified at surgery, underwent 
investigational procedures. Baseline measurements at the included implant were 
performed on the same day as the surgical procedure. 
Radiographic measurements 
 
Intra-oral peri-apical radiographs were obtained of implants in a standardized way 
using Eggen holders and long cone equipped dental X-ray units. All radiographs 
presenting study implants were digitalized, coded and evaluated by a computer 
program (MATLAB® Vers. R2013b software for MAC OS 10.9; Mathworks, Natick, 
MA, USA). 
Radiographs were studied by changing parameters in black and white modus as well 
as in colour look-up tables. Measurements from a well-defined reference point at the 
coronal part of the implant body taken at baseline 6 and 12-months visits were: 
vertical defect depth and width, marginal bone level and horizontal bone level (Figure 
2, supplementary Figure 3). Based on these measurements, changes in vertical 
defect depth, marginal bone level, % defect fill and % defect resolution from baseline 
to 12 months were calculated. 
The most coronal confluent aggregation of bone or bone with graft material was used 
to define marginal and horizontal bone levels. Titanium particles without visible 
mineralized tissue adjacent to the implant did not count as most coronal bone-to-
implant contact. Likewise single isles of bone or bone-like material were not 
considered. 
Implant length and width or known dimensions of implant-threads were used as 
reference for calibration of measurements. Radiographic evaluations were initially 
performed by an independent physicist (PNJ), with high expertise in image analysis, 
who was not involved in other aspects of the study. He had previously been 
Page 8 of 30
http://mc.manuscriptcentral.com/jdr
Journal of Dental Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 8 
extensively trained by a periodontist experienced in oral radiology on sample images 
on a LCD-display with a resolution of 2560 x 1600 and a 32-Bit colour pixel depth. All 
measurements performed were saved as graphics placed on top of the 
corresponding image and were then independently confirmed by two periodontists. 
No double measurements of radiographs were performed. If differences were > 0.1 
mm, the three calibrated investigators re-analysed the respective implant together to 
reach a consensus (Enkling et al. 2011a,b, 2013).  
 
Clinical measurements 
For proper standardization between baseline and re-evaluation data, only one 
examiner took all the clinical measurements in each study centre. All probing 
measurements were obtained with a pressure (0.20-0.25N) sensitive probe (Click-
Probe®, Kerr, Switzerland) to the nearest mm at 6 sites per implant (mesio-buccal, 
buccal, disto-buccal, disto-palatal, palatal, mesio-palatal).  
At baseline and 12 months visits, the following recordings were taken: 
• Probing pocket depths (PPD) 
• Bleeding on probing (BoP)  
• Suppuration (PUS) 
• Plaque 
BoP and PUS at the affected implants were assessed within 30 seconds following 
probing. 
At surgery intraoperative measurements included: 
• Defect depth (mm) at the deepest point 
• Defect circumference (degrees),  
• Defect walls (number)  
• Defect width (mm) 
Sample size calculation/Power Analysis 
The calculation of the number of patients to be treated (sample size) was based on a 
previous proof-of-concept single-centre RCT (Wohlfahrt et al. 2012) and the primary 
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 9 
objective to detect a true mean difference of at least 2 mm between test and control 
treatment for radiographic defect fill after 12 months. With a level of significance of 
alpha = 0.05 in a two-sided hypothesis and a power of 90 %, the number of patients 
needed was 48.  Assuming a dropout rate of about 30% the total number of patients 
required was 60. 
Randomization, Allocation concealment and Blinding 
Patients were randomly assigned to treatment modality by using a computerized 
randomization scheme prepared prior to study initiation and to treatment in blocks of 
6. The patients were allocated to either reconstruction of the defect with PTG (Test) 
or closure of the flap after implant debridement (OFD/Control). Documentation of 
treatment allocation for each patient was placed in separate, sealed opaque 
envelopes that were opened and revealed to the surgeon after debridement of the 
defect and implant surface was finished. Clinical examiners and the statistician 
remained blinded to the treatment assigned. 
Interventions 
Surgical Procedure   
A non-submerged surgical technique was used for both test and control sites. 
Following administration of local anaesthesia flap elevation procedure included an 
intra-crevicular incision around the implant. Full thickness mucoperiosteal flaps were 
raised on the buccal and lingual aspect to gain access to the complete peri-implant 
defect and to the implant surface. The size of the flap was determined by supra-
crestal incisions extending mesial and distal of the implant site. Vertical incisions into 
the vestibule at a distance of at least one tooth/implant from the implant were 
performed as necessary for adequate access. Granulation tissue was removed using 
titanium curettes (HuFriedy®, Chicago, IL, USA) and the exposed implant surfaces 
were cleaned mechanically by using a rotary titanium brush (Tigran PeriBrush™, 
Tigran Technologies, Malmö, Sweden) and decontaminated chemically with 3% H2O2 
for 1 minute followed by rinsing with saline for 60 seconds (2 x 20 ml).  
Following treatment allocation in accordance to randomization, titanium granules 
(Tigran™, Tigran Technologies, Malmö, Sweden) were applied into the intraosseous 
defects of the test sites. After insertion of the granules, excess material was carefully 
removed. Flaps were then repositioned and sutured back into position using 
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 10
monofilament non-resorbable sutures. 
Peri-operative protocol 
Patients were prescribed a combination of Amoxicillin 500 mg 3/day and 
Metronidazole 400 mg 2/day for 8 days, starting one day prior to surgery. Patients 
were then instructed to rinse twice daily with chlorhexidine mouth rinse (0.2%) for 1 
month. The patients used brushes as usual in other areas of the mouth. Anti-
inflammatory and analgesic therapy was prescribed (Ibuprofen 3 x 600 mg/day) 
during the first two days and according to the individual needs thereafter.  
The sutures were removed after 7 to 14 days and patients were instructed in the use 
of soft toothbrushes and soft interdental brushes (super soft – Gentle/Implant Care 
TePe, Malmö, Sweden) in the surgical area. 
Patients were recalled at 6 weeks, 3, 6, 9 and 12 months after surgery for 
professional oral hygiene procedures with supra-gingival debridement and hygiene 
instructions as needed. 
Pre-defined early withdrawal criteria were: 
• non healing infections 
• substantial exfoliation of graft material (rejection) 
• local intolerance to graft material 
• recurrence of active peri-implantitis at the test site  
• loosening of implant 
• poor patient compliance, not returning for control visits 
 
Statistical Analysis 
Primary outcome was defect fill as assessed by changes of radiographic marginal 
bone level and vertical defect depth.  
Secondary outcomes were changes in: 
• PPD  
• BoP  
• Suppuration/Pus  
• Plaque  
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 11
Analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). 
All patients included in the study had surgery performed and were analyzed for side 
effects. Four patients were excluded from analysis because there were no data 
available at 12 months (Figure 1). 
Statistical analysis of primary efficacy endpoint measures was performed using 
centre as stratification variable. As a significant interaction between baseline 
measurements and treatment was observed for vertical defect depth measures a 
stratified Wilcoxon test (Lehmann 1975, van Elteren 1960) was applied. 
Treatment intergroup comparisons of secondary efficacy endpoints were based on 
least squares means obtained from the ANCOVA model. Means for each treatment 
group and differences between treatment groups are presented along with 
associated 95% Confidence Intervals (CI) as well as p-values for differences within 
treatment groups. 
The statistical hypotheses for the Primary Outcome defect fill (mm) was:  
H0: ∆  Marginal bone level Test – ∆  Marginal bone level control = 0 
H1: ∆  Marginal bone level Test – ∆  Marginal bone level control ≠ 0 
and : 
H0: ∆  Vertical defect Test – ∆  Vertical defect control = 0 
H1: ∆  Vertical defect Test – ∆  Vertical defect control ≠ 0 
For percent changes the statistical hypotheses were based on: 
% D e f e c t  r e s o l u t i o n = (Vertical defect baseline- Vertical defect 12months)/( Vertical defect baseline) x100 
% Defect Fill =  (Marginal bone level baseline- Marginal bone level 12months )/( Vertical defect baseline) x100  
 
If the p-value from this analysis fell below 0.05 in both mesial and distal 
measurements it was concluded that there was a statistically significant difference in 
average change between the two treatment groups.  
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 12
Results 
Between February 2010 and December 2013 a total of 105 patients were 
consecutively recruited at the 5 study centres (16 – 36 per centre). Seventy patients 
fulfilled the primary and 63 the secondary inclusion criteria and were randomized to 
test (n = 33) and control (n = 30) group. Four patients of the control group refused to 
participate at the 12 months recall appointment and were lost to follow-up. The 
number of participants per centre ranged from 10 to 13. Baseline characteristics and 
demographics for subjects in the two study groups are presented in Table 1.  
Radiographic and clinical findings are presented in Table 2 and effects of treatment 
as changes in radiographic and clinical parameters are presented in Table 3. 
Significantly higher reductions of vertical defect depth and gains in marginal bone 
level favoured the PTG reconstructed group (<0.0001). After 12 months the mean 
gain of marginal bone level for the Test group was 3.61/3.56 mm (mesial/distal) 
compared to 1.05/1.04 mm (mesial/distal) in the OFD group. This corresponded to a 
mean defect fill for the PTG treated sites of 79.00/74.22% (mesial/distal) compared 
with 23.11%/21.89% (mesial/distal). 
No differences in defect width and horizontal bone level changes could be observed 
(supplementary table 4).  
The test group showed a mean reduction in PPD of 2.8 mm (SD 1.3) compared to 2.6 
mm (SD 1.4) in the OFD group. Reductions for BoP amounted to 56.1% for the test 
compared to 44.9% for control group. Intergroup differences for PPD or BoP 
reduction were not found to be significantly different. 
In both treatment groups 30% of implants showed disease resolution by absence of 
any bleeding on probing, whereas 30% (test) and 23% (control) of implants 
demonstrated successful peri-implantitis therapy by the use of a composite outcome 
that also included shallow pockets and no further bone loss (Table 2). 
None of the patients treated demonstrated subjective or objective side effects, such 
as pronounced pain, manifest inflammatory reactions, discoloration of the 
surrounding mucosa, or patient morbidity, beyond what is normally expected for 
similar surgical procedures. 
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Discussion 
The present randomized multi-national, multicentre trial demonstrated additional 
benefits following reconstructive surgery with application of porous titanium granules 
in combination with an open flap non-submerged debridement procedure for the 
treatment of advanced peri-implant osseous defects when compared to open flap 
debridement alone. Mean radiographic defect fill, as the primary outcome, amounted 
to 3.6 mm translating into a mean defect fill of about 79%, which was significantly 
higher than 1.0 mm (22%) observed in the control group. Thus, the study null-
hypothesis assuming no difference in defect fill could be rejected.  
With regard to secondary outcome measures, there were no statistically significant 
differences in reduction of pocket depths and bleeding on probing. Both surgical 
treatment modalities resulted in marked improvements of the clinical conditions. 
To the best of our knowledge, this is the largest published randomized trial to 
evaluate the effectiveness of reconstructive peri-implant surgery and one of the very 
few that used open flap debridement for comparison, as demanded by a recent 
systematic review (Koshkam et al. 2013). It adopted the current guidelines for quality 
of methods and reporting for studies of the efficacy of therapeutic approaches to peri-
implant diseases (Graziani et al. 2012) from a recent consensus conference, where 
multi-center approaches were encouraged (Sanz and Chapple 2012). The fact that 
different surgeons in a variety of settings treated a wide range of implants types 
enhances the generalizability of the obtained results. 
There are also some limitations inherent in any study of the present design. First, a 
radiographic examiner cannot be blinded due to the use of a radiopaque bone 
substitute. We tried to compensate for this shortcoming by employing 3 independent 
calibrated examiners. Second, the amount of bone fill has to be interpreted with 
caution, whenever radiopaque bone substitutes are used. In this regard the choice of 
a distinctly visible material such as titanium granules may have advantages 
compared to other non/slow-resorbable bone substitutes (such as for example 
natural bone mineral/deproteinized bone xenograft), as it can be more clearly 
distinguished from the surrounding bone. The possibility of pure “x-ray-cosmetics” 
becomes less likely. Third, it has to be realized that re-osseointegration/regeneration 
cannot be evaluated by a clinical study. Regarding the healing of PTG applied to 
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 14
peri-implant osseous defects, 2 case reports, one using human histology and another 
a re-entry procedure, can help to interpret the radiographic findings of the present 
study. Human histology demonstrated that grafting of a peri-implant defect with PTG 
could support re-osseointegration of the implant with newly formed bone (Wohlfahrt 
et al. 2011), and re-entry surgery of a treated peri-implant defect after 6 months 
revealed a complete integration of the bone replacement material in new bone, with 
no signs of loose particles (Wohlfahrt and Lyngstadaas 2012). Further evidence 
comes from recently published clinical studies on the use of PTG for sinus 
augmentation, where biopsies employing histological and micro-CT analyses 
confirmed osteoconductive properties of porous titanium granules (Dursun et al. 
2015, Lyngstadaas et al. 2015, Verket et al. 2013, Vandeweghe et al. 2013). 
Another possible shortcoming in the present study was the fact that the inter-
examiner agreement for the clinical parameters could not be assessed due to 
logistical and financial constraints. All clinical examiners were very experienced, had 
shown good intra-examiner reproducibility in the past and measures were taken to 
standardize the probing assessment as much as possible. In particular, the use of a 
pressure sensitive probe was considered to be very important for the reliable and 
reproducible assessment of peri-implant bleeding (Lang et al. 2000). Any bias 
resulting from a possible low inter-examiner reproducibility would have affected to a 
similar extent both the test and the control group and therefore most likely not the 
outcome of the efficacy analysis of this RCT. 
Another possible confounder could be the distribution of different implant types in the 
test and control group.  Even though at present there are no data from clinical studies 
on the influence of implant microstructure and other surface characteristics on the 
response to reconstructive treatment the possible impact of such implant features on 
the outcomes can not be ruled out. 
All four of the dropout patients were from the control group. This could also have an 
impact on the results.  We have checked the baseline characteristics of the drop-outs 
and were able to confirm that they were not outliers in any aspect.  
The results of the present study compare favourably with the weighted means of 2.17 
mm (95% CI: 1.46-2.87 mm), 2.1 mm (95% CI: 1.47-2.72 mm), and 2.16 mm (95% 
CI: 1.36-2.96 mm), respectively, for radiographic defect fill reported in recent 
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systematic reviews on the outcomes of reconstructive/regenerative procedures in the 
treatment of peri-implantitis (Khoshkam et al. 2013; Chan et al. 2014).  
Comparing the results of the present multicentre RCT with the previous single-center 
RCT on the use of PTG (Wohlfahrt et al. 2012) similar differences were seen. In their 
study, using a submerged design for the healing phase, radiographic peri-implant 
defect fill was significantly increased with application of PTG (2.0 +/- 1.7 mm) 
compared with non-grafted control group (0.1 mm +/- 1.9 mm). Event though both 
studies used systemic antibiotics, differences in flap design, and in particular 
characteristics of the peri-implant osseous defects treated might be responsible the 
difference in the magnitude of the outcomes (Schwarz et al. 2010).  Another 
contributing factor could be the implant decontamination procedure. Wohlfahrt et al. 
(2012) used titanium curettes and 24% EDTA, whereas in the present study a 
titanium brush in combination with 3% H2O2 was employed. When comparing control 
groups of the two studies, differences in radiographic defect fill are obvious, as our 
control group showed an average defect reduction of 1 mm after 12 months. In 
contrast, in the earlier investigation the non-grafted control group did not improve at 
all after treatment (0.1mm +/- 1.9mm). In the present study anti-infective OFD using a 
titanium brush with H2O2 decontamination of the implant surface even led to 
complete radiographic bone fill up to the implant shoulder in one implant.  
Finally, a retrospective cohort study using PTG for peri-implantitis lesions in 18 
implants in 16 patients reported a reduction of mean bone loss from 4.4 to 2.3 mm 
(Mijiritsky et al. 2013). 
With regard to secondary outcomes, the present study showed marked clinical 
improvements by reduction in inflammation (BoP and suppuration) and reduction in 
mean PPD in both treatment groups. Mean BoP reductions of 56% in the test group 
compare favourably with the weighted mean of 45.8% in a recent systematic review 
(Koshkam et al. 2013). The proportion of implants with absence of any bleeding at 6 
sites amounted to 30% in both groups. Likewise, mean PPD reductions of 2.8 mm in 
the test group are in concert with the weighted mean of 2.9 mm in a recent meta-
analysis (Koshkam et al. 2013). PPD reductions in the control group are in 
agreement with a recent meta-analysis of studies using access flap and debridement 
(Chan et al. 2014). In the interpretation of these findings a significantly improved full 
mouth plaques score in the control group, which was not seen in the test group, 
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should be kept in mind. 
The use of composite therapeutic endpoints for the surgical management of peri-
implantitis has been recently recommended (Sanz and Chapple 2012) and they were 
applied in the present study. Disease resolution by presence of shallow pockets 
without any bleeding at 6 sites of the implants and no further bone loss could be 
demonstrated for 30% of implants in the test and 23% of implants in the control 
group. While such an endpoint would be the ideal goal of peri-implantitis therapy and 
measure for success no other studies have reported such composite outcomes 
(Heitz-Mayfield and Mombelli 2014). 
In the present study, no barrier membrane was used to cover the bone substitute. 
For the contained defects this additional measure which would add more costs was 
not felt to be necessary, even though a recent meta-analysis demonstrated higher 
PD and BOP reduction following grafts and barrier membranes than following grafts 
alone (Chan et al. 2014). A long-term follow up study showed a significantly better 
outcome following natural bone mineral in combination with a collagen membrane 
compared to a resorbable hydroxyapatite after 4 years (Schwarz et al. 2009).  In 
contrast, Roos-Jansaker et al. (2015) found no additional effect from the application 
of a barrier membrane to a bone graft. Future studies will have to show whether 
membranes or the use of a non/slow-resorbable bone substitute are of key 
importance to ensure long-term stability of the results of reconstructive peri-implant 
surgery.  
Within the limitations of the present study, it can be concluded that surgical treatment 
approaches which included the use of a titanium brush for implant surface 
dcontamination and adjunctive systemic antibiotics have shown promising results for 
the treatment of advanced peri-implant osseous defects. No significant differences 
were observed regarding the clinical outcomes bleeding and pocket reduction as well 
as for complete resolution of peri-implantitis between test and control procedures. 
The radiographic findings have to be interpreted with caution, as it is difficult to 
discern biomaterial and newly formed osseous tissue. Therefore, the relevance and 
potential benefit of an enhanced radiographic defect fill following application of 
porous titanium granules into 3- and 4-wall defects will have to be evaluated by 
further histological studies and a long-term clinical follow up.  
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Figure legends  
Figure  1:  CONSORT flow chart.  
Figure  2:  Radiographic measurements at baseline and after 12 months. 
Supplementary Figure 3:  Radiographs showing peri-implant osseous defects before 
and after treatment for Test (a, b, c) and Control group (d, e, f). 
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A Vertical Defect Depth  
B Defect Width 
C Marginal bone level 
D Horizontal bone level 
E Implant shoulder  
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Table 1 :  Patient Characteristics at Baseline. 
 
 Test (PTG) 
(n=33) 
Control (OFD) 
(n=30) 
Age (years), mean (SD) 57.7 (12.6) 59.1 (12.2) 
Male (n) 16 (48.5%) 11 (36.7%) 
Female (n) 17 (51.5%) 19 (63.3%) 
Reason for placing implants   
Caries 10 (30.3%) 9 (30.0%) 
Other 6 (18.2%) 2 (6.7%) 
Periodontitis 11 (33.3%) 16 (53.3%) 
Trauma 6 (18.2%) 3 (10.0%) 
History of Periodontal Treatment   
No 13 (39.4%) 10 (33.3%) 
Unknown 3 (9.1%) 0 (0%) 
Yes 17 (51.5%) 20 (66.7%) 
Smoking status   
Current 11 (33.3%) 7 (23.3%) 
Former 9 (27.3%) 11 (36.7%) 
Non-smoker 13 (39.4%) 12 (40.0%) 
Implant Brands   
Ankylos 2 1 
Astra (OsseoSpeed) 6 4 
Dyna 1  
Friadent Xive 1 2 
Nobel Biocare 10 8 
SIC Invent  1 
Straumann (Standard neck) 5 5 
TRI MAX  1 
TMI  3 2 
Zimmer 4 2 
3i Biomet 1 4 
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Table 2: Radiographic and Clinical Parameters at Baseline and 12 Months. 
 
 
 
*BoP Bleeding Score Index out of 6 sites per implant. 
** PUS | Plaque Score out of 6 sites per implant 
*** at 6 implant sites 
  Test (OFD+PTG)  
n = 33 
Control (OFD) 
n = 26 
 
 BL 12M P-value BL 12M P-value  
Vertical defect depth (mm)  
Mean (SD) 
mesial 4.64 
(1.95) 
1.03 
(1.35) 
<0.0001 3.98 
(2.50) 
2.88 
(1.86) 
NS  
 
distal 4.63 
(2.26) 
1.06 
(1.51) 
<0.0001 3.79 
(1.75) 
2.72 
(1.77) 
NS  
Marginal Bone level (mm) 
Mean (SD) 
mesial 5.55 
(2.30) 
1.98 
(1.99) 
<0.0001 4.63 
(2.68) 
3.63 
(2.34) 
0.0001  
distal 5.41 
(2.72) 
1.96 
(1.95) 
<0.0001 4.45 
(2.23) 
3.63 
(2.32) 
0.0007  
Defect width (mm) 
Mean (SD) 
mesial 2.53 
(1.25) 
1.33 
(1.78) 
<0.0001 2.28 
(0.89) 
2.11 
(1.07) 
NS  
distal 2.65 
(1.57) 
1.55 
(1.88) 
<0.0001 2.34 
(1.11) 
1.92 
(1.41) 
NS  
Horizontal bone level (mm) 
Mean (SD) 
mesial 0.91 
(1.31) 
0.95 
(1.44) 
NS 0.64 
(1.06) 
1.30 
(3.24) 
NS  
 distal 0.78 
(1.40) 
0.92 
(1.27) 
NS 0.66 
(1.33) 
0.90 
(1.35) 
NS  
PPD (mm) 
Mean (SD) 
 6.3 
(1.3) 
3.5 
(1.5) 
<0.0001 6.3 
(1.6) 
3.5 
(1.1) 
<0.0001  
 
mesial 6.9 
(2.0) 
3.7 
(1.8) 
<0.0001 6.3 
(1.8) 
3.9 
(1.3) 
<0.0001  
 
distal 6.5 
(1.3) 
3.6 
(1.5) 
<0.0001 6.6 
(1.6) 
3.6 
(1.2) 
<0.0001  
BoP (%)* 
Mean (SD) 
 89.4 
(20.7) 
33.3 
(31.7) 
<0.0001 85.8 
(23.9) 
40.4 
(37.1) 
<0.0001  
PUS (%)** 
Mean (SD) 
 27.8 
(34.0) 
1.0 
(4.2) 
<0.0001 25.9 
(33.1) 
1.3 
(4.6) 
<0.0001  
PI (%)** 
Mean (SD) 
 25.8 
(36.8) 
24.8 
(36.3) 
NS 21.0 
(28.7) 
10.3 
(20.0) 
0.02  
Implants (%) with:         
Absence of BoP ***  0 10 
(30.3) 
 0 8 
(30.8) 
  
PPD ≤4 mm*** and Absence of 
BoP*** and no further bone loss  
 0 10 
(30.3) 
 0 6 
(23.0) 
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Table 3:  Change in Radiographic and Clinical Parameters between Baseline and 12 
Months.  
 
 
Mean (SD) 
 
 Test 
(OFD+PTG) 
 
 Control 
(OFD) 
 
Test vs. 
Control 
p-value 
Vertical defect depth 
(mm) 
mesial -3.61 (1.96) 
 
-1.05 (1.42) <0.0001 
min:max 
 
-9.4 : -0.3  -5.7 : 1.9 
 
 distal -3.56 (2.07)  -1.04 (1.34) <0.0001 
min:max 
 
-9.0 : 0.3  -3.9 : 1.6 
 
Marginal bone level 
(mm) 
mesial 
 
-3.58 (2.05) 
 
 
-0.96 (1.35) <0.0001 
min:max  -9.9 : 0.3  -4.7 : 1.9  
Estimate (95% CI)  -3.41 (-3.94 : -2.89)  -1.21 (-1.81 : -0.62)  
 distal -3.45 (2.16)  -0.84 (1.14) <0.0001 
min:max  -9.0 : 0.3  -3.9 : 1.0  
Estimate (95% CI)  -3.28 (-3.81 : -2.75)  -1.11 (-1.72 : -0.50)  
      
Defect resolution (%)* mesial 78.83 (27.25)  24.10 (40.01) <0.0001 
 distal 77.95 (28.82)  25.79 (36.02) <0.0001 
Defect fill (%) ** mesial 79.00 (29.85)  23.11 (46.28) <0.0001 
 distal 74.22 (36.33)  21.89 (30.16) <0.0001 
PPD   -2.8 (1.3)  -2.6 (1.4) NS 
Estimate (95% CI)  -2.81 (-3.17: -2.46)  -2.66 (-3.06 : -2.25)  
 mesial -3.2 (1.9)  -2.2 (1.6) NS 
Estimate (95% CI)  -3.02 (-3.47 : -2.56)  -2.47 (-2.99 : -1.96)  
 distal -2.9 (1.5)  -2.9 (1.6) NS 
Estimate (95% CI)  -3.02 (-3.47 : -2.56)  -2.71 (-3.14 : -2.29)  
BoP (%)***  56.1 (30.5)  44.9 (38.2) NS 
Estimate (95% CI)  -55.34 (-65.44 : -45.24)  -45.52 (-56.97 : -34.07)  
PUS (%)****  -23.2 (32.8)  -25.6 (32.7) NS 
Estimate (95% CI)  -22.79 (-27.69 : -24.59)  -25.99 (-31.53 : -20.45)  
PI (%)*****  -1.0 (37.5)  -11.5 (34.2) NS 
Estimate (95% CI)  -0.43 (-10.50 : -9.74)  -12.91 (-24.39 : -1.44)  
      
*defined as: (Vertical defect baseline- Vertical defect 12months)/( Vertical defect baseline) x100 
** defined as: (Marginal bone level baseline- Marginal bone level 12months )/( Vertical defect baseline) x100  
***BoP Bleeding score index  out of 6 sites per implant.  
**** PuS Score out of 6 sites per implant. 
***** Plaque Score out of 6 sites per implant. 
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Supplementary Table 4:  Changes in Radiographic Defect Width and Horizontal Bone 
Level between Baseline and 12 Months. 
 
 
 
Means (SD)  
 
 
Test 
(OFD+PTG) 
Control (OFD) 
 
 
Test vs. 
Control 
p-value 
 
Defect width  
(mm) 
    
 
Estimate (95% CI) 
mesial 1.20 (1.58) 
-1.16 (-1.59 : -0.73) 
0.12 (0.77) 
-0.21 (-0.70 : 0.28) 
NS 
 
 
Estimate (95% CI) 
distal 1.10 (1.65) 
-1.06 (-1.57 : -0.55) 
0.35 (1.39) 
-0.47 (-1.06 : 0.13) 
NS 
 
Horizontal bone level 
(mm) 
    
 
Estimate (95% CI) 
mesial 0.04 (0.97) 
-0.01 (-0.77 : 0.76) 
0.63 (3.09) 
-0.63 (-0.23 : 1.50) 
NS 
 
 
Estimate (95% CI) 
distal 0.15 (1.07) 
0.16 (-0.15 : 0.46) 
0.19 (0.75) 
0.18 (-0.17 : 0.54) 
NS 
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Supplementary Figure 3:  Radiographs showing peri-implant osseous defects before 
and after treatment for Test (a, b, c) and Control group (d, e, f). 
 
Test group: 
 
a ) Baseline         b ) 6 Months               c ) 12 Months 
 
             
 
 
Control group: 
 
d ) Baseline       e) 6 Months          f) 12 Months 
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CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3, 4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons n/a 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 5 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
9, 10 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
8, 10 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 8, 9 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 9 
8b Type of randomisation; details of any restriction (such as blocking and block size) 9 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
9 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
9 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 9 
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CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions  
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 11 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses n/a 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
12 
13b For each group, losses and exclusions after randomisation, together with reasons 12 
Recruitment 14a Dates defining the periods of recruitment and follow-up 12 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1,2 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
12 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
Table 3 
Sup. Table 4 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Table 2, 3 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
n/a 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 12,13 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 14,15 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 14, 15, 16 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 15, 16, 17 
Other information  
Registration 23 Registration number and name of trial registry ClinicalTrials 
NCT02406001 
Protocol 24 Where the full trial protocol can be accessed, if available ClinicalTrials 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Tigran 
Technologies 
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